Gapping down
In reaction to disappointing earnings/guidance:
- ELVT -29.8%, TREX -12.3%, FTSI -12.2%, TXRH -11.7%, APTI -11%, CGNX -9.7% (also authorized the purchase of up to $200 million of common stock; increases quarterly cash dividend to $0.05 per share from $0.045 per share), RMBS -9.5% (also appoints Luc Seraphin as President, CEO), ALSN -9.3%, CYH -8.8%, VNOM -8.1%, CHK -6.5%, IRMD -6.3%, AEIS -6.2%, MAS -5.3%, CTSH -4.7%, CBL -4.5%, PFE -3.8%, APPF -2.8%, ACCO -2.2%, AOS -2.2%, TPR -2%, ERJ -1.9%, HIIQ -1.8%, SCI -1.6%, BBVA -1.6%, ETN -1.5%, OLN -0.8%, MKSI -0.7%, AMKR -0.5%, INCY -0.5%
M&A news:
- LEN -1.5% ( agrees to sell Rialto Investment and Asset Management business to investment funds managed by Stone Point Capital for $340 mln)
Other news:
- EGRX -6.4% (Eagle Pharma's fulvestrant formulation has not met the primary bioequivalence endpoints evaluating Eagle's formulation compared to FASLODEX; also provides guidance)
- ASRT -5.6% (appoints Daniel A. Peisert CFO, effective upon the retirement of current CFO Phil B. Donenberg on November 30)
- CMTA -3.6% (prices offering of 5.3 mln shares of common stock at $13.25 per share)
- ALKS -2.8% (FDA release briefing documents ahead of November 1 AdCom covering Buprenorphine and Samidorphan (ALKS 5461) in MDD)
- ACAD -2.7% (announces departure of CFO Todd S. Young, effective October 31, and names Elena Ridloff Interim CFO)
Analyst comments:
- LUV -1.4% (downgraded to to Underweight from Neutral at JP Morgan)
- SNH -0.8% (Underweight from Equal-Weight at Morgan Stanley)
![]()